Chemical Shift Encoding-based Water-fat Magnetic Resonance Imaging in Spinal Tumors

November 20, 2022 updated by: Peking University Third Hospital
Fat composition of the spinal tumors is positively correlated with classification and differential diagnosis of benign and malignant tumors.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Chemical shift encoding-based water-fat magnetic resonance imaging (MRI) is a non-invasive method that provides quantitative information about the biochemical water-fat composition of bone marrow and skeletal muscle in vivo.

Study Type

Observational

Enrollment (Anticipated)

150

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • China
    • Beijing
      • Beijing, Beijing, China, 100089
        • Recruiting
        • Peking University Third Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Adults with spinal tumors

Description

Inclusion Criteria:

  • Pathological biopsy of a patient with diagnosed spinal tumor lesion, and preoperative examination Chemical shift encoding-based water-fat MRI was performed.

Exclusion Criteria:

  • Recurrent neoplasms; Lesion diameter < 1 cm; Poor image quality.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Patients with benign spinal tumor
Diagnostic test: Chemical shift encoding-based water-fat MRI
Chemical shift encoding-based water-fat magnetic resonance imaging (MRI): a non-invasive method
Patients with intermediate spinal tumor
Diagnostic test: Chemical shift encoding-based water-fat MRI
Chemical shift encoding-based water-fat magnetic resonance imaging (MRI): a non-invasive method
Patients with malignant spinal tumor
Diagnostic test: Chemical shift encoding-based water-fat MRI
Chemical shift encoding-based water-fat magnetic resonance imaging (MRI): a non-invasive method

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Type of tumor
Time Frame: One month before treatment
Pathological diagnosis
One month before treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Peking University Third Hospital

Investigators

  • Study Chair: Ning Lang, Peking University Third Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 1, 2022

Primary Completion (Anticipated)

December 1, 2023

Study Completion (Anticipated)

December 31, 2023

Study Registration Dates

First Submitted

November 20, 2022

First Submitted That Met QC Criteria

November 20, 2022

First Posted (Actual)

November 30, 2022

Study Record Updates

Last Update Posted (Actual)

November 30, 2022

Last Update Submitted That Met QC Criteria

November 20, 2022

Last Verified

August 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • M2022403

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Spinal Tumor

Clinical Trials on Chemical shift encoding-based water-fat MRI

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bosnia & Herzegovina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe